Turn Therapeutics Inc. filed a Form 8-K on July 28, 2026, to furnish an updated investor presentation under Item 7.01 of Regulation FD. The presentation outlines the company's pipeline, including GX-03 for moderate-to-severe atopic dermatitis, with Phase 2 topline results expected in Q4 2026. It also details plans for Phase 3 trials in onychomycosis starting in Q1 2027 and Phase 2a trials in hidradenitis suppurativa in Q2 2027. Financial highlights include a cash balance of $11.2 million as of March 31, 2026, and a cash runway extending into Q3 2027. Turn Therapeutics Inc. operates in the biotechnology industry, developing precision immunomodulation therapies for inflammatory skin diseases.
